32,873 research outputs found
Heterogeneity of Kaposi's sarcoma-associated herpesvirus (HHV-8)-positive effusions
No full text[No abstract available
Hybrid phenotypes and lineage promiscuity in acute leukemia
No full textClinical data indicate that AL are heterogeneous diseases with variable responsiveness to chemotherapeutic agents. Based on this evidence, the efforts of most investigators are aimed at providing rapid identification of AL features predictive of distinct prognostic outcomes. A considerable number of reagents (including MoAb and molecular probes) available from commercial sources has been widely used for diagnostic purpose, leading to the identification of "inappropriate" antigen expression and to diagnoses of "mixed" AL (M-AL). The latter still lacks adequate definition and identification criteria, but is frequently reported as a novel entity associated with poor clinical outcome. The use of more accurate methodologic approaches, as well as a better elucidation of normal hemopoietic cell characteristics suggest that true M-AL occur quite rarely: the features of normal precursor counterparts are more frequently conserved. "Ectopic" marker expression, however, which should not be interpreted as reflecting lineage infidelity, may in some instances explain different clinical courses in AL patients. Further elucidation of normal stem cell features, and adequate standardization of AL immunophenotyping--to be performed under proper technical conditions--are needed for a better evaluation of M-AL, both in terms of diagnosis and classification, as well as regarding their clinical significance
Additive effects in the induction of apoptosis in leukemic cells by WT1 and BCR-ABL specific siRNA
No full textPatient-reported outcomes in hematology: Is it time to focus more on them in clinical trials and hematology practice?
No full textIn less than 2 decades, major clinical advances have been made in various areas of hematologic malignancies. Clinicians and patients now frequently face challenging choices regarding various treatments that are often similar in regard to safety or clinical effectiveness; hence, medical decision making has grown in complexity. For example, several novel drugs have been developed as oral agents, introducing an additional challenge in patient management, such as ensuring an optimal adherence to therapy in order to maximize drug effectiveness. This rapidly changing scenario provides a rationale for a more systematic collection of patient-reported outcomes (PRO) in clinical research and routine care. In the former case, PRO may help to better understand overall treatment effectiveness of a new drug being tested. In the latter case, it may aid in making more informed, individualized treatment decisions in daily practice by obtaining more accurate information on the actual symptom burden experienced by the patient. In any case, evaluating PRO requires making several, and often challenging, decisions depending, for example, on the population being studied and the specific setting. Therefore, if PROs are to fulfill their potential of generating clinically meaningful data that robustly inform patient care, special attention should be given to methodological rigor. We outline the value of a more systematic and rigorous implementation of PRO assessment in the current hematology arena, by providing some real world examples of how PRO data have contributed in better understanding the value of new therapies. We also discuss practical considerations in PRO assessment in clinical research
Logistica e mobilità sostenibile- Position paper di Merita
No full textLo sviluppo delle infrastrutture e dei trasporti per la mobilità delle persone
e la movimentazione delle merci, contribuisce in maniera sostanziale
alla Coesione del nostro Paese: il divario tra il Nord e il Sud è, in entrambi
i casi, tanto clamoroso che il PNRR destina alla voce «Infrastrutture e
Trasporti» ben più della quota generale del 40 per cento dei fondi che il
Piano Nazionale di Ripresa e Resilienza alloca al Mezzogiorno. Questa
strategia si sviluppa coerentemente con gli orientamenti della transizione
ecologica verso obiettivi di mobilità e logistica sostenibile
Clinical usefulness of arsenic trioxide in the treatment of acute promyelocytic leukemia
No full text- …
